







an Open Access Journal by MDPI

# PARP Enzymes, ADP-Ribose and NAD+ Metabolism in Cancer

Guest Editors:

### Prof. Dr. Péter Bay

Department of Medical Chemistry, Faculty of Medicine, University of Debrecen, H-4032 Debrecen, Hungary

#### Dr. José Yélamos

1. Cancer Research Program, Hospital del Mar Medical Research Institute, 08003 Barcelona, Spain 2. Laboratory of Immunology, Department of Pathology, Hospital del Mar, 08003 Barcelona, Spain

Deadline for manuscript submissions: **closed (30 April 2023)** 

# **Message from the Guest Editors**

We are arranging a Special Issue in the journal Cancers (Impact Factor: 6.639). This Special Issue of *Cancers* will consist of research and review articles on "PARP Enzymes, ADP-ribose, and NAD+ Metabolism in Cancer". It will focus on selected papers from the FEBS Advanced Lecture Course conference on "PARP2021: Research on the Family of Poly(ADP-ribose) Polymerases" (https://parp2021.febsevents.org/), that takes place in Barcelona (Spain) on 7–10 September 2021, but all manuscripts relevant to the topic are welcome.

The aim of this Special Issue is to offer an up-to-date overview of the current developments in the PARP arena and contribute with new original results













an Open Access Journal by MDPI

## **Editor-in-Chief**

### Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

## **Message from the Editor-in-Chief**

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

### **Author Benefits**

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

#### **Contact Us**